Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-fluorouracil + cyclophosphamide + doxorubicin + interferon-α2b
- Development stage
- Unknown
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous, Intramuscular
01
Overview
This is a four-drug combination regimen consisting of three chemotherapeutic agents—5-fluorouracil (an antimetabolite), cyclophosphamide (an alkylating agent), and doxorubicin (an anthracycline)—together with interferon-α2b (a recombinant cytokine). The three chemotherapy drugs are commonly used together as the CAF regimen for breast cancer and other solid tumors. Interferon-α2b is added to potentially enhance antitumor activity. Mechanistically, 5-fluorouracil inhibits thymidylate synthase, disrupting DNA synthesis; cyclophosphamide crosslinks DNA strands to prevent cell division; doxorubicin intercalates into DNA and inhibits topoisomerase II; while interferon-α2b binds to the type I interferon receptor complex (including IFNAR2), activating JAK/STAT signaling pathways that induce antiproliferative and immunomodulatory effects. This combination has been studied in advanced breast cancer[1][3][4].
- Other names
- CAF plus interferon alfa-2bcyclophosphamide, doxorubicin, 5-fluorouracil, and interferon alfa-2b combination
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)TS (Thymidylate synthase)DNA interstrand cross-linkIFNAR1 (Interferon alpha/beta receptor 1)IFNAR2 (Interferon alpha/beta receptor subunit 2)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on 5-fluorouracil + cyclophosphamide + doxorubicin + interferon-α2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-fluorouracil + cyclophosphamide + doxorubicin + interferon-α2b.